WFA
NRIX icon

Wipfli Financial Advisors’s Nurix Therapeutics NRIX Stock Holding History

Wipfli Financial Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
+67
New +$1.06K ﹤0.01% 2461

Other funds holding NRIX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wipfli Financial Advisors's NRIX Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Nurix Therapeutics (NRIX) in Q3 2022: 67 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2461 among its holdings.

118 funds tracked by Wall St. Rank hold NRIX as of Q3 2022.

  • Wipfli Financial Advisors held 67 shares of Nurix Therapeutics worth $1K as of Q3 2022.
  • Nurix Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Nurix Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2461 holding.
  • 118 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.